Singapore markets closed

Talaris Therapeutics, Inc. (TALS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.60-1.29 (-14.51%)
At close: 04:00PM EDT
7.70 +0.10 (+1.32%)
Pre-market: 08:25AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 368.60M
Enterprise value 145.73M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.63
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.61

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-39.00%
S&P500 52-week change 3-5.66%
52-week high 319.82
52-week low 35.70
50-day moving average 38.13
200-day moving average 311.75

Share statistics

Avg vol (3-month) 341.82k
Avg vol (10-day) 352.37k
Shares outstanding 540.31M
Implied shares outstanding 6N/A
Float 817.03M
% held by insiders 114.52%
% held by institutions 178.96%
Shares short (28 Apr 2022) 41.14M
Short ratio (28 Apr 2022) 430.05
Short % of float (28 Apr 2022) 44.72%
Short % of shares outstanding (28 Apr 2022) 42.75%
Shares short (prior month 30 Mar 2022) 41.16M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-18.62%
Return on equity (ttm)-31.06%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -56.13M
Net income avi to common (ttm)-56.79M
Diluted EPS (ttm)-1.51
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)225.53M
Total cash per share (mrq)5.44
Total debt (mrq)3.4M
Total debt/equity (mrq)1.50
Current ratio (mrq)28.32
Book value per share (mrq)5.51

Cash flow statement

Operating cash flow (ttm)-47.22M
Levered free cash flow (ttm)-29.49M